

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



April 26, 2019

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
NSE Code – SUNPHARMA

Sub: Clarification/confirmation on news item

Dear Sirs,

With reference to your email seeking clarification on the news item which appeared in the Newspaper- The Indian Express Sources dated April 25, 2019, titled "US FDA Finds quality, data issues at Dadra plant of Sun Pharma", we hereby submit our response as follows:

a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order.

Response: The US FDA conducted an inspection of Sun Pharmaceutical Industries Ltd.'s Dadra facility from March 22, 2019 to March 29, 2019. At the conclusion of the inspection, the agency issued a Form 483, with 11 observations. The Company has submitted its response to the US FDA within the stipulated timeline. Sun Pharma is committed to addressing these observations promptly.

b) The material impact of this article on the Company.

Response: There is no material impact of this article on the Company

c) Whether company are aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations.

Response: No

Kindly let us know in case you require any further clarification.

Yours faithfully,

For Sun Pharmaceutical Industries Limited,


Ashok Bhuta
Compliance Officer

CC to : BSE Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.
BSE Code– 524715